

1 **Title:** Two Stage Hierarchical Group Testing Strategy to Increase SARS-CoV-2 Testing Capacity at an Institution of
2 Higher Education: A Retrospective Analysis

3 **Authors:** Troy Ganz¹, Markus Waithe-Alleyne¹, Deirdre Slate¹, Rachel Donner¹, Kevin Hines¹, Gyorgy
4 Abel^{1,2}, Jared Auclair¹

5 1. Life Science Testing Center, Northeastern University, Burlington, Massachusetts, USA

6 2. Lahey Hospital & Medical Center, Burlington, Massachusetts, USA

7 Text pages: 9; Tables: 1; Figures: 3

8 **Corresponding Authors:**

9 **Jared Auclair, Ph.D.**

10 Technical Supervisor, Life Science Testing Center

11 Northeastern University Innovation Campus in Burlington

12 Department of Chemistry and Chemical Biology

13 145 South Bedford Street

14 Burlington, MA 01803

15 j.auclair@northeastern.edu

16 781-238-8402

17 **Gyorgy Abel, M.D.**

18 Lahey Hospital & Medical Center

19 41 Mall Road

20 Burlington, MA 01805

21 gyorgy_abel@hms.harvard.edu

22 781.744.8951

23 **Abstract:**

24 Population testing for severe acute respiratory syndrome 2 (SAR-CoV-2) is necessary owing to the possibility of
25 viral transmission from asymptomatic cases, yet scarcity of reagents and equipment has added to the cost-
26 prohibitive implementation of screening campaigns at institutions of higher education. The high analytical
27 sensitivities of leading nucleic acid amplification diagnostic methods allow for group testing to increase testing
28 capacity. A feasibility study was performed using an optimized testing configuration model for pooling three, five,
29 and ten samples. Following the standard RNA extraction and purification workflow for quantitative reverse
30 transcriptase polymerase chain reaction (RT-qPCR) method using Thermo Fisher TaqPath™ COVID-19 multiplex
31 primers and probes for the ORF1ab, N, and S genes, matrix and dilution effects were assessed using pooled
32 negative samples as the diluent. Probit analysis produced a limit of detection of 16075 (ORF1ab), 1308 (N), and
33 1180182 (S) genomic copy equivalents per milliliter. Trials comparing neat to 1:5 dilution for 34 weak-to-strongly
34 positive samples demonstrated average threshold cycle (C_T) shifts of 2.31 ± 1.16 (ORF1ab), 2.23 ± 1.12 (N), and
35 2.79 ± 1.40 (S). Notwithstanding observed S gene dropouts, the false negative rate was unaffected. As the ratio of
36 asymptomatic positive to symptomatic positive SARS-CoV-2 infected individuals was approximately 4:1 and the
37 average prevalence was 0.16% since we started testing in August 2020, pooled testing was identified as a viable,
38 cost-effective option for monitoring the Northeastern University community.

39 **Introduction:**

40 The emerging pandemic of coronavirus disease (COVID-19), sourced from the novel strain of beta-coronavirus
41 known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has had a severe impact on global
42 healthcare systems [1,2]. Institutions of higher education (IHE) have been confronted with the conflicting
43 obligations to guarantee a standard quality of education while ensuring the safety of their faculty, staff, and
44 students during the pandemic. For universities with shared living, dining, transportation, and classroom learning
45 arrangements, the greater requirements of risk management must be weighed against the economic loss of closing
46 for an indeterminate period [3,4]. Further pressures are imposed upon IHE in urban environments as positive
47 correlations of transmission have been observed with factors such as reduced air quality and higher population
48 density [5]. As with other respiratory infections, transmission is facilitated by viral shedding in the upper
49 respiratory tract that may release viral particles in the form of aerosols ($\leq 5 \mu\text{m}$) or droplets ($> 5 \mu\text{m}$) to contaminate
50 the surrounding air or surfaces, and spread via fomites, coughing, sneezing, and exhalation from symptomatic, as
51 well as pre-symptomatic and asymptomatic, carriers [6]. Along with recommended measures for risk management
52 such as physical distancing, obligatory personal hygiene, and mask wearing, a rigorous screening and surveillance
53 campaign provides the most effective response.

54 Quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) is the most sensitive method for early
55 detection of SARS-CoV-2 when compared to other available analytical methodologies (e.g., lateral flow
56 immunoassay), which require larger viral titers or longer periods of seroconversion following infection [7,8].
57 Nasopharyngeal, nasal (nares), or oropharyngeal respiratory samples, and saliva have been evaluated through
58 several RT-qPCR platforms; the added benefit being upper respiratory collections are less invasive than
59 venipuncture for serological testing, resulting in better patient compliance [8]. Drawbacks coincide with the sharp
60 increase in global demand for medical and testing supplies such as personal protective equipment (PPE; gloves,
61 gowns, surgical and N95 masks), collection swabs and containers, transport and lysis buffers, nucleic acid
62 extraction and amplification kits, consumables such as micropipette tips, analytical equipment, as well as qualified

63 technical personnel as the high-complexity format of RT-qPCR testing schema requires a reliable supply chain of
64 critical materials.
65 Group testing, or sample pooling, is an attractive method to increase testing capacity without a need for
66 additional resources or training. Since the introduction of the methodology by Dorfman in 1943, subsequent
67 studies have generated models to predict optimal group sizes within a test's analytical sensitivity and relative cost
68 as factors of dilution and individual repeat testing, or deconvolution, must be considered [10,11]. Pressured by the
69 COVID-19 pandemic, investigators have sought to validate SARS-CoV-2 group testing on available molecular
70 platforms [12,13,14,15]. The following investigation sought to define an ideal group size with respect to the cost of
71 the current protocol while retaining an acceptable analytical sensitivity.

72 **Methods:**

73 **Sample Collection**

74 The study was conducted at the Life Science Testing Center (LSTC; Burlington, MA, USA) for Northeastern
75 University (NEU) students, faculty, and staff within the United States Northeast (MA, ME) regional campuses.
76 Population surveillance includes sample collection from symptomatic, pre-symptomatic, asymptomatic, and
77 uninfected individuals.
78 Anterior nasal swabs were collected in 3 mL BD Vacutainer® (without additives) tubes and transported dry
79 at ambient temperature. Processing involved addition of 3 mL viral transport medium (VTM; Redoxica, Little Rock,
80 AR, USA) and shaking at 1000 rpm for 5 minutes. Specimens are stable for <72 hours at 2-8°C and indefinitely at -
81 80°C.

82 **Modeling**

83 Our prospective workflow can be modeled using an adaptive two-stage hierarchical algorithm, whereby results
84 from the master pool direct repeat testing of the individual samples. An optimal testing configuration is a result of
85 several parameters including disease prevalence, group size, and analytical sensitivity and specificity. Significant to
86 our protocol, success of the MS2 phage extraction control defines an additional retesting criterion that may be
87 interpreted to impact the master pool. Utilizing a web-based R application (www.chrisbilder.com/shiny/), a

88 variable was included to reflect the probability of MS2 failure (invalid) to achieve estimated reductions for pools of
89 size 3, 5, and 10. Sensitivity was set to 95% based on the calculated limit of detection, while specificity was set to
90 99% under the combined influence of the MS2 control and operator review. Results were depicted to distinguish
91 the number of tests required for 1000 samples as informed by both the Shiny app and the modified version for
92 each group size with respective invalid rates and prevalence using Excel.

93 **RNA Extraction and RT-qPCR**

94 SARS-CoV-2 RNA was extracted from 200 μ L of sample using the MagMAX™ Viral/Pathogen Nucleic Acid Isolation
95 Kit (Thermo Fisher Scientific, Waltham, MA, USA) on semi-automated Agilent™ Bravo liquid handlers (Agilent
96 Technologies, Santa Clara, CA, USA). Briefly, each well in a 1 mL 96-well plate is prepared with 5 μ L proteinase K,
97 200 μ L sample, 275 μ L lysis buffer/binding beads, and 5 μ L MS2 phage control. It is then shaken for 2 minutes at
98 1,050 rpm and incubated for 5 minutes at 65°C. Incubation on a magnetic plate at room temperature allows
99 aspiration of waste material and a sample undergoes three cycles of resuspension/aspiration in 165 μ L wash
100 buffer, 165 μ L 80% ethanol, and 50 μ L elution buffer, respectively. After final separation event, 50 μ L of purified
101 RNA solution is transferred to a fresh 1 ml 96-well plate.

102 RT-qPCR was performed according to the U.S. FDA emergency use authorization (EUA) instructions for use (IFU)
103 for TaqPath™ COVID-19 Combo kit (Thermo Fisher Scientific, Waltham, MA, USA), which is a multiplex assay to
104 detect SARS-CoV-2 open reading frame (ORF) 1ab, nucleocapsid (N), and spike (S) genes, in addition to a spiked-
105 in MS2 phage extraction control (reporter dyes FAM, VIC, ABY, and JUN, respectively). The sample volume of 25 μ L
106 involves 10 μ L of purified RNA and 15 μ L of reaction mix that includes TaqPath™ 1-Step Multiplex Master Mix (No
107 ROX™), primers, and probes. Thermal profile parameters involve a 2-minute UNG incubation cycle at 25°C, a 10-
108 minute reverse transcriptase incubation cycle at 53°C, a 2-minute activation cycle at 95°C, followed by 40 cycles of
109 a 3-second denaturation at 95°C and 30-second anneal/extension cycle at 60°C on Applied Biosystems™ 7500 Fast
110 Dx Real-Time PCR Instrument (Thermo Fisher Scientific, Waltham, MA, USA).

111

112 Relative genome copy equivalents (GCE) were calculated via averaged standard curves using all (16) 7500 Fast Dx
113 RT-PCR instruments in house, whereby threshold cycle (C_T) measurements for 5000, 1000, 500, 250, 100, 50, 10,
114 and 5 gce/ μ L were evaluated for three lots of TaqPath™ COVID-19 Positive Control.

115 **Matrix Effect Study**

116 The C_T values for 6 moderate-to-weakly positive samples [ORF1ab:26.19 \pm 4.68; N:27.15 \pm 4.35; S:26.61 \pm 5.06] were
117 compared in parallel dilution series of 1:2, 1:4, 1:8, 1:16, 1:32, and 1:64 using either VTM (standard) or Negative
118 Sample Pool (matrix), prepared from 16 confirmed negative samples, as diluent. Results were converted to a
119 Matrix Effect factor using the formula: $ME = -(((Matrix\ C_T/Standard\ C_T) * 100) - 100)$, whereby a factor of
120 100 is subtracted from the percent ratio of results to produce a normalized value indicating the magnitude of the
121 suppression or enhancement imparted by the matrix diluent. To correct for the inverse relationship of C_T value to
122 concentration, the equation was negated; therefore, a negative ME value indicates suppression, while a positive
123 ME value indicates enhancement.

124 **Pooled Probit Analysis**

125 Replicates of moderate-to-weak positive sample pools [12 – ORF1ab:27.76 \pm 0.82, N:28.85 \pm 0.18, S:28.28 \pm 0.54 C_T ; 8
126 – ORF1ab:27.08 \pm 0.22, N:28.07 \pm 0.25, S:27.41 \pm 0.34 C_T] were produced in two series dilution assays using negative
127 sample pool material as the diluent. The first involved 12 replicates ranging from neat to 1:2, 1:4, 1:8, 1:16, 1:32,
128 1:64, 1:128, and 1:256 dilutions while the second involved 8 replicates ranging from neat to 1:10, 1:20, 1:40, 1:80,
129 1:160, 1:320, 1:640, and 1:1280 dilutions; negative sample pools additionally assayed neat separately to rule out
130 presence of interfering substances. Results that met the TaqPath™ method qualitative criteria of $<37\ C_T$ were
131 counted in the proportion of success rate and the average C_T value for each gene of those results were converted
132 to a relative GCE per milliliter. The Probit of the success rate was produced with Excel® formula 5+NORMSINV(P)
133 and was plotted against the \log_{10} of the GCE. The 95% confidence interval was calculated from the linear regression
134 analysis to evaluate the limit of detection (LoD).

135 **1:5 Dilution Trials**

136 Thirty-four strong-to-weak positive samples [ORF1ab:21.52±5.37; N:22.11±5.36; S:21.77±5.71] were assayed neat
137 and at 1:5 dilution, in singlet, using negative sample material as the diluent to determine a predictable shift in
138 C_T value. The neat sample was extracted from 200 μ L and the 1:5 dilution was extracted from 40 μ L of positive
139 sample diluted in 160 μ L of negative sample material.

140 **Results:**

141 **Demographics**

142 Since LSTC establishment in July 2020, the site has performed over 500,000 tests (ca. January 2021) with
143 an overall positivity rate of 0.16%. Cohort descriptions for the positive sample repository used in this
144 study included symptomatic (19.6%; 44% male, 56% female) and asymptomatic (80.4%; 55% male, 45% female)
145 patients within their respective age ranges: 18-24 (63%), 25-31 (17%), 32-49 (13%), and >50 (7%).

146 **Matrix Effect Study**

147 Of the 77 data-points generated, 31 trials (40.3%) demonstrated signal suppression by the negative sample matrix,
148 whereas 46 trials (59.7%) demonstrated an enhanced signal. Focusing on the range of 2 to 8 pooled samples, a
149 more equally distributed effect is observed with 48% of 46 datapoints showing average suppression of -1.64 ± 1.77 ,
150 -1.32 ± 1.27 , and -4.46 ± 6.19 while 52% showed an average enhancement of 3.67 ± 4.32 , 1.53 ± 0.89 , and 3.28 ± 2.87 for
151 ORF1ab, N and S gene, respectively (Figure 1). Additionally, 37% of the 2-8 sample pools reported a ME within one
152 unit. Thus, with average C_T values of 27.6 ± 0.58 , 27.9 ± 0.34 , and 29.2 ± 0.44 , a matrix effect of 1 would elicit a
153 C_T value shift of ± 0.28 , ± 0.28 , and ± 0.29 for ORF1ab, N, and S genes, respectively. Furthermore, only 17% of 2-8
154 sample pools reported an ME greater than 5, which translates to a C_T value shift of >1 cycle.

155 **Pooled Probit Analysis**

156 The LOD for each of the SARS-CoV-2 genes using negative sample pool as diluent was 16,075 gce/mL,
157 1,308 gce/mL, and 1,180,182 gce/mL for the ORF1ab, N, and S genes, respectively. Regressions for the ORF1ab and
158 N gene were more reliable than for the S gene ($R^2 = 0.28$), which may be indicative of the reaction mechanism.
159 A qualitative LOD would implement TaqPath™ testing algorithm of 2/3 genes resulted with C_T of <37 , and LSTC
160 intends to deconvolute a pool with at least 1/3 genes present (Table 1).

161 **1:5 Dilution Trials**

162 Diluting positive SARS-CoV-2 sample in negative sample material at a 1:5 dilution produced an average shift of the
163 C_T value by 2.31 ± 1.16 , 2.23 ± 1.12 , and 2.79 ± 1.40 cycles for ORF1ab, N, and S gene, respectively (Figure 2). Paired t-
164 test analysis comparing neat and diluted groups for each gene showed no statistically significant difference, with p-
165 values of 0.0878, 0.0988, and 0.0527 for OFR1ab, N, and S gene, respectively. Consistent with the matrix effect
166 study and probit analysis, the S gene exhibited the least sensitivity with 12% of trials losing signal (Figure
167 2C). Nevertheless, each trial met TaqPath™ testing algorithm for 2/3 genes testing positive to require
168 deconvolution.

169 **Discussion:**

170 This study has established an optimal pool size of five specimens to provide a cost-effective bandwidth with
171 respect to prevalence and rate of repeat testing while insignificantly impacting the analytical sensitivity for the
172 Thermo Fisher™ TaqPath™ COVID-19 Combo Kit.

173 The pandemic has disproportionately affected the mission of IHE with an impact ranging from increased
174 maintenance costs to the academic performance of students. Pre-symptomatic COVID-19 infections are credited
175 with a greater rate of transmission than asymptomatic infections and a correlation with age has been observed
176 with younger populations demonstrating higher rates of asymptomatic cases [16,17]. In the Northeastern
177 University community 80.4% of positive cases from August 2019 to January 2021 were asymptomatic individuals,
178 of which 76% were between the age of 18-27; this data is consistent with results from the University of Georgia
179 [18]. The Northeastern University student community is required to test every three days (+/- 1 day) and
180 employees on site five days a week are expected to test at least twice a week.

181 Under non-pooling conditions, the sum of assays informed by the MS2 control could be expressed as $E = n + 1$,
182 where E is the expected number of tests and n is the probability of repeat testing due to absence of MS2 signal.
183 Pursuant to LSTC protocol, an MS2 failure is repeated once and further representation for the total assays could be
184 expressed as $E = (n + 1) + (n^2)$. Our modeling indicates the number of repeated testing due to MS2 failure is
185 higher at lower group sizes. It may serve as the deciding factor at a prevalence upwards of 1% since labor costs

186 may outweigh a less than 50% reduction in materials (Figure 3). Furthermore, group testing is an environmentally
187 conservative measure that aligns with ‘green laboratory’ efforts by minimizing the requirements for non-
188 biodegradable materials, toxic chemical waste, and energy consumption [19]. Additional stage hierarchical and
189 array methods may also increase group testing efficiency for diseases of low prevalence [20].
190 Multiplex RT-qPCR has been sought to increase assay sensitivity for the detection of SARS-CoV-2, yet inherent
191 limitations arise from increased competition in reaction kinetics [21]. The genomic architecture of SARS-CoV-2
192 exhibits extensive secondary structure with regions consisting of high base pairing content thought to be
193 mechanistically advantageous for the transcription and thermodynamic stability of sub-genomic RNA [22]. Further
194 consideration that retro-transcription occurs from the 3’ direction suggests cDNA production from the N gene with
195 less deviation than the S and ORF1ab genes. Concurrent with our results, the N gene demonstrated the greatest
196 stability within the negative sample matrix, which was confirmed by a limit of detection 1 and 3 orders of
197 magnitude less than the ORF1ab and S genes, respectively. Recent identification of a SARS-CoV-2 variant of
198 concern (VOC) 202012/01 has been associated with several mutations in the S gene including a deletion at position
199 69 and 70 to cause S-gene target failure by the TaqPath COVID-19 method [23]. Due to the enhanced binding
200 interactions of VOC 202012/01 spike protein with the target angiotensin converting enzyme 2 (ACE-2), estimates
201 suggest the increased transmissibility will permit strain predominance in the United States by spring 2021 [24].
202 While no genomic sequence data was available for the samples used in this study, it is important to consider the
203 international nature of the university population as many Northeastern students are from abroad. Accurate
204 assessment of the origins of predominant strains is further challenged by the transience of personal interactions in
205 urban environments. It is also notable that Northeastern campuses in Boston, Massachusetts and Portland, Maine
206 experience significant in-state commuter traffic.
207 Results from this retrospective study are consistent with recent reports confirming an insignificant effect on the
208 false negative rate for pools of similar size; additionally, our average C_T value shifts were precise [14,15]. Probit
209 analysis is applicable to the bimodal output of RT-qPCR for LoD analysis. As all constituent samples of positive
210 pools initially tested positive for all three genes, the data supports a mechanistic basis for the substantial reduction

211 in S-gene sensitivity, which may align with current S-gene target failure hypotheses [23,24]. Our report pioneered a
212 quantification of the matrix effect for RT-qPCR to improve analyte stability. This study was not able to comment on
213 the logistical impacts of deconvolution, which could potentially prolong the <48-hour turn-around-time regularly
214 scheduled testing may require, yet the evidence presented in this study supports pooling as a means of addressing
215 supply chain restrictions. Aliquoting samples to 96-well plates prior to pooling limits operator errors and improved
216 workflow of maintaining operator audit logs and having a well-functioning laboratory information management
217 system (LIMS) program enables easy results review.

218

219 **Conflict of Interest**

220 The authors declare no conflict of interest.

221 **Ethical Statement**

222 Retrospective samples were deidentified for study purposes in accordance with IRB approval by the Northeastern

223 University Office of Human Subject Research Protection (HSRP).

224 **Acknowledgements:**

225 The authors would like to thank Dr. Christopher Bilder for accommodating our inquiries as well as acknowledge the

226 tireless efforts of all at the LSTC.

227

228 **References:**

- 229 1. Zhu, N., D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu,
230 G. Wu, G. F. Gao, W. Tan: A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of*
231 *Medicine* 2020, 382(8):727-733
- 232 2. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, Zhang C, Boyle C, Smith M, Phillips JP: Fair Allocation of
233 Scarce Medical Resources in the Time of Covid-19. *New England Journal of Medicine* 2020, 382:2049-2055. doi:
234 10.1056/NEJMs2005114
- 235 3. Paltiel, A. D., A. Zheng and R. P. Walensky: Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of
236 College Campuses in the United States. *JAMA Network Open* 2020, 3(7): e2016818.
- 237 4. Cheng, S. Y., C. J. Wang, A. C. Shen and S. C. Chang: How to Safely Reopen Colleges and Universities During COVID-19:
238 Experiences From Taiwan. *Ann Intern Med* 2020. 173(8): 638-641.
- 239 5. Sharifi, A. and A. R. Khavarian-Garmsir: The COVID-19 pandemic: Impacts on cities and major lessons for urban planning,
240 design, and management. *Sci Total Environ* 2020, 749: 142391.
- 241 6. Jayaweera, M., H. Perera, B. Gunawardana and J. Manatunge: Transmission of COVID-19 virus by droplets and aerosols: A
242 critical review on the unresolved dichotomy. *Environ Res* 2020 188: 109819.
- 243 7. Corman, V. M., O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D. K. Chu, T. Bleicker, S. Brünink, J. Schneider, M. L. Schmidt,
244 D. G. Mulders, B. L. Haagmans, B. van der Veer, S. van den Brink, L. Wijsman, G. Goderski, J. L. Romette, J. Ellis, M. Zambon,
245 M. Peiris, H. Goossens, C. Reusken, M. P. Koopmans and C. Drosten: Detection of 2019 novel coronavirus (2019-nCoV) by
246 real-time RT-PCR. *Eurosurveillance* 2020, 25(3).
- 247 8. Sethuraman, N., S. S. Jeremiah and A. Ryo: Interpreting Diagnostic Tests for SARS-CoV-2. *Jama* 2020 323(22): 2249-2251.
- 248 9. Ward, S., A. Lindsley, J. Courter and A. Assa'ad: Clinical testing for COVID-19. *J Allergy Clin Immunol* 2020, 146(1): 23-34.
- 249 10. Robert, D.: The Detection of Defective Members of Large Populations. *The Annals of mathematical statistics* 1943, 14(4):
250 436-440.
- 251 11. Hitt, B.D.: *Group testing identification: Objective functions, implementation, and multiplex assays* [Doctoral dissertation,
252 University of Nebraska-Lincoln] 2020, UNL Digital Commons. <http://digitalcommons.unl.edu/>
- 253 12. Abdalhamid, B., C. R. Bilder, J. L. Garrett and P. C. Iwen: Cost Effectiveness of Sample Pooling to Test for SARS-CoV-2.
254 *Journal of Infection in Developing Countries* 2020, 14(10): 1136-1137.

- 255 13. Yelin, I., N. Aharony, E. S. Tamar, A. Argoetti, E. Messer, D. Berenbaum, E. Shafran, A. Kuzli, N. Gandali, O. Shkedi, T.
256 Hashimshony, Y. Mandel-Gutfreund, M. Halberthal, Y. Geffen, M. Szwarwort-Cohen and R. Kishony: Evaluation of COVID-
257 19 RT-qPCR Test in Multi sample Pools. *Clinical Infectious Disease* 2020, 71(16): 2073-2078.
- 258 14. Alcoba-Florez, J., H. Gil-Campesino, D. García-Martínez de Artola, O. Díez-Gil, A. Valenzuela-Fernández, R. González-
259 Montelongo, L. Ciuffreda and C. Flores: Increasing SARS-CoV-2 RT-qPCR testing capacity by sample pooling. *International*
260 *Journal of Infectious Disease* 2021, 103: 19-22.
- 261 15. Chong, B. S. W., T. Tran, J. Druce, S. A. Ballard, J. A. Simpson and M. Catton: Sample pooling is a viable strategy for SARS-
262 CoV-2 detection in low-prevalence settings. *Pathology* 2020, 52(7): 796-800.
- 263 16. Moghadas, S. M., M. C. Fitzpatrick, P. Sah, A. Pandey, A. Shoukat, B. H. Singer and A. P. Galvani: The implications of silent
264 transmission for the control of COVID-19 outbreaks. *PNAS USA* 2020, 117(30): 17513-17515.
- 265 17. Oran, D. P. and E. J. Topol Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. *Annals of Internal*
266 *Medicine* 2020, 173(5): 362-367
- 267 18. Ebell, M. H., C. Chupp and M. Bentivegna: A high proportion of SARS-CoV-2-infected university students are asymptomatic.
268 *Journal of Family Practice* 2020, 69(9): 428-429.
- 269 19. Lopez, J. B., D. Jackson, A. Gammie and T. Badrick: Reducing the Environmental Impact of Clinical Laboratories. *Clinical*
270 *Biochemical Review* 2017, 38(1): 3-11.
- 271 20. Hou, P., J. M. Tebbs, D. Wang, C. S. McMahan and C. R. Bilder: Array testing for multiplex assays. *Biostatistics* 2020, 21(3):
272 417-431.
- 273 21. Ishige, T., S. Murata, T. Taniguchi, A. Miyabe, K. Kitamura, K. Kawasaki, M. Nishimura, H. Igari and K. Matsushita: Highly
274 sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories.
275 *Clin Chim Acta* 2020, 507: 139-142.
- 276 22. Tavares, R. C. A., G. Mahadeshwar, H. Wan, N. C. Huston and A. M. Pyle: The global and local distribution of RNA structure
277 throughout the SARS-CoV-2 genome. *Journal of Virology* 2020
- 278 23. Bal, A., G. Destras, A. Gaymard, K. Stefic, J. Marlet, S. Eymieux, H. Regue, Q. Semanas, C. d'Aubarede, G. Billaud, F. Laurent,
279 C. Gonzalez, Y. Mekki, M. Valette, M. Bouscambert, C. Gaudy-Graffin, B. Lina, F. Morfin and L. Josset: Two-step strategy for
280 the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France,
281 August to December 2020. *Eurosurveillance* 2021, 26(3).

- 282 24. Galloway, S. E., P. Paul, D. R. MacCannell, M. A. Johansson, J. T. Brooks, A. MacNeil, R. B. Slayton, S. Tong, B. J. Silk, G. L.
283 Armstrong, M. Biggerstaff and V. G. Dugan: Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-
284 January 12, 2021. *Morbidity and Mortality Weekly Report* 2021, 70(3): 95-99.

Tables:

Analyte	Replicates detected at respective GCE/mL				slope	y-int	R ²	Probit (95% CI) GCE/mL
ORF1ab	1495	995	280	163	1.24	1.43	0.91	16075
	[8/12]	[4/8]	[3/8]	[2/12]				
N	823	447	298	148	2.71	-1.79	0.82	1308
	[7/8]	[6/8]	[3/12]	[2/8]				
S	-	3733	2147	425	0.72	2.27	0.28	1180182
	-	[5/8]	[2/12]	[2/8]				

Table 1: Limit of Detection (LoD) Results of SARS-CoV-2 ORF1ab, N and S gene in negative sample material. Ratio of successes for trials that produced less than 100% hit rate provided with corresponding concentration in genome copy equivalents per milliliter. Slope, y-intercept, and R-squared coefficient of probit analysis used to achieve limit of detection.

Figures:




Figure 1




Figure 2




Figure 3

Figure Legends:

Figure 1: Matrix effect (ME) of diluting positive SARS-CoV-2 sample in negative sample material at 1:2, 1:4, 1:8, 1:16, 1:32, and 1:64 series dilutions. ME factor describes relative enhancing (positive value), or suppressive (negative value) effect of negative sample material on SARS-CoV-2 detection.

Figure 2: Dilution trials comparing neat to 1:5 dilution of positive SARS-CoV-2 sample in negative patient material. Cycle threshold (C_T) values for ORF1ab (A), N (B), and S (C) gene observed for each trial ($p > 0.05$).

Figure 3: Number of PCR reactions required for testing 1,000 patient samples with respect to pool size, prevalence rate. Dark grey prevalence rates: predicted number of tests including the invalid rate (n). Light grey prevalence rates: predicted number of tests without inclusion of invalid rate.